Akkus Erman, Karaoğlan Beliz Bahar, Kayaalp Mehmet, Turmuş Utkucan, Akyol Cihangir, Utkan Güngör
Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara, Türkiye.
Ankara University Cancer Research Institute, Ankara, Türkiye.
Int J Cancer. 2025 Jun 15;156(12):2340-2351. doi: 10.1002/ijc.35336. Epub 2025 Jan 30.
Early-onset colorectal cancer (EOCRC) is an alarming entity worldwide. Yet, stage-specific characteristics and prognosis in localized and synchronous metastatic EOCRC are not well-defined. Two cohorts of CRC patients (localized and synchronous metastatic) were evaluated, defining EOCRC as the diagnosis <50 years old. Five hundred sixty-eight patients were included (n = 432 localized, 14.4% [n = 62] EOCRC and n = 136 synchronous metastatic, 20.6% [n = 28] EOCRC). 93.5% of localized and 96.5% of synchronous metastatic EOCRC patients were symptomatic at diagnosis. Among localized patients, female gender (58.1% vs. 40%, p = .008), perineural invasion (41.9% vs. 24.9%, p = .005), folinic acid, 5-fluorouracil, and oxaliplatin chemotherapy (45.2% vs. 25.2%, p = .003), and perioperative chemotherapy cycles (9.21 [± 3.10] vs. 7.98 [± 2.92], p = .006) were higher in EOCRC compared with ≥50-year. Median recurrence-free survival (RFS) and overall survival were not reached in either group (p = .234 and p = .831). Only RAS mutant status was associated with RFS (Hazard ratio: 7.09 [95% confidence interval (CI): 1.87-26.76], p < .001) in EOCRC. Among synchronous metastatic patients, urgent surgery (32.1% vs. 11.1%, p = .014) and local treatments (39.3% vs. 20.4%, p = .037) were more frequent in EOCRC. Median progression-free survival and overall survival in the EOCRC and ≥50 years were 8.07 months (95% CI: 5.03-12.97) vs. 10.03 months (95% CI, 8.40-13.10) (p = .450) and 18.57 months (95% CI, 13.33-43.03) vs. 19.83 months (95% CI, 16.07-27.30) (p = .833), respectively. Synchronous metastatic EOCRC more frequently underwent urgent surgery (32.1% vs. 8%, p = .008) and had RAS mutation (43.5% vs. 16.7%, p = .032) than localized EOCRC. This study suggests that localized and synchronous metastatic EOCRC patients may have different characteristics than average onset, without survival differences. Implementation of stage-specific characteristics into daily practice is necessary for decision-making processes in these young patients.
早发性结直肠癌(EOCRC)在全球范围内是一个令人担忧的疾病实体。然而,局限性和同步转移性EOCRC的特定分期特征及预后尚未明确界定。对两组结直肠癌患者(局限性和同步转移性)进行了评估,将EOCRC定义为诊断时年龄<50岁。共纳入568例患者(n = 432例局限性患者,其中14.4%[n = 62]为EOCRC;n = 136例同步转移性患者,其中20.6%[n = 28]为EOCRC)。93.5%的局限性EOCRC患者和96.5%的同步转移性EOCRC患者在诊断时有症状。在局限性患者中,EOCRC患者的女性比例(58.1%对40%,p = 0.008)、神经周围侵犯(41.9%对24.9%,p = 0.005)、亚叶酸、5-氟尿嘧啶和奥沙利铂化疗(45.2%对25.2%,p = 0.003)以及围手术期化疗周期(9.21[±3.10]对7.98[±2.92],p = 0.006)均高于≥50岁的患者。两组患者的无复发生存期(RFS)和总生存期的中位数均未达到(p = 0.234和p = 0.831)。在EOCRC中,只有RAS突变状态与RFS相关(风险比:7.09[95%置信区间(CI):1.87 - 26.76],p < 0.001)。在同步转移性患者中,EOCRC患者进行急诊手术(32.1%对11.1%,p = 0.014)和局部治疗(39.3%对20.4%,p = 0.037)更为频繁。EOCRC组和≥50岁组的无进展生存期和总生存期的中位数分别为8.07个月(95%CI:5.03 - 12.97)对10.03个月(95%CI,8.40 - 13.10)(p = 0.450)和18.57个月(95%CI,13.33 - 43.03)对19.83个月(95%CI,16.07 - 27.30)(p = 0.833)。与局限性EOCRC相比,同步转移性EOCRC更常进行急诊手术(32.1%对8%,p = 0.008)且RAS突变率更高(43.5%对16.7%,p = 0.032)。这项研究表明,局限性和同步转移性EOCRC患者可能具有与平均发病年龄患者不同的特征,但生存无差异。将特定分期特征应用于日常实践对于这些年轻患者的决策过程是必要的。